Immunomedics soars 106% after Gilead agrees to acquire the cancer-drug company for $21 billion

5 years ago 1 min read

Gilead expects the deal to immediately bolster its revenue growth, and to be neutral to accretive to adjusted earnings per share in 2023.

Leave a Reply

Your email address will not be published. Required fields are marked *

More Stories

1 min read

Record Korean Cases; Trader’s Guide to Rollout: Virus Update

5 years ago
1 min read

California Hits Record; Trader’s Guide to Rollout: Virus Update

5 years ago
1 min read

AstraZeneca to Buy Alexion for $39 Billion in Rare-Disease Push

5 years ago

You may have missed

1 min read

Record Korean Cases; Trader’s Guide to Rollout: Virus Update

5 years ago
1 min read

LGBTQ-inclusive books are hard to find. So these groups started sending them to schools.

5 years ago
1 min read

At least six arrested as ‘Stop the Steal’ protesters and counter-protesters clash in Washington, DC

5 years ago
1 min read

Brazil rolls out COVID-19 vaccination plan

5 years ago